Novo Nordisk Appoints New Leaders of European and North American Regions
- Details
- Category: Novo Nordisk
Novo Nordisk announced that with effect from 1 January 2008 the company has appointed Martin Soeters to take up the position as senior vice president of Region Europe. Martin Soeters is currently senior vice president of Novo Nordisk North America and president of Novo Nordisk Inc., the company's US affiliate. Martin Soeters will be replaced by Jerzy Gruhn who will take up the position as senior vice president of Novo Nordisk North America from the same date. Jerzy Gruhn is currently vice president of the Europe East region within Region Europe.
AstraZeneca Enhances Clinical Research Capabilities in China
- Details
- Category: AstraZeneca
AstraZeneca today announced a strategic partnership with Peking University 3rd Hospital to open its first Clinical Pharmacology Unit (CPU) in China. The unit aims to enhance local clinical research capabilities and speed up access to new medicines to benefit Chinese patients.
European Commission Approval for biosimilar epoetin alfa
- Details
- Category: Product
Sandoz has become the first company to develop and receive European Commission approval for its biosimilar epoetin alfa, achieving another important milestone in its efforts to bring high quality, cost-effective biological medicines to patients. The European Commission's decision to grant this approval followed a positive opinion in June from the European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP), which reviews medicines scientifically for the Commission.
Takeda's Investigational Compound TAK-536 Enters into Phase 2 Clinical Stage in Japan
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited ("Takeda") announced that its investigational compound TAK-536 has entered into Phase 2 clinical stage in Japan. TAK-536 is an angiotensin receptor blocker (ARB) discovered by Takeda and its mechanism of action is to lower blood pressure by inhibiting action of a vasopressor hormone Angiotensin II.
Results Were Consistent in Patients Switched to Angiox from Other Antithrombin Therapy
- Details
- Category: Product
Patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), or angioplasty, experienced nearly 50 percent less bleeding at 30 days and comparable mortality at one-year when treated with Angiox(R) (bivalirudin) alone compared to unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor (GPI), according to data from the ACUITY trial.
Strategic Acquisition of MedPointe Inc Completed
- Details
- Category: Financial
Meda announced that it had signed an agreement to acquire all shares in MedPointe. This strategic acquisition has now been completed and consolidation of MedPointe starts immediately. Meda plans to give further information on the acquisition and its impact on Meda in the interim report for the third quarter - to be released on 30 October 2007.
Award for Bilobil in Poland
- Details
- Category: Product
The first place in the national competition "Consumer's Laurel 2007" in the category "Drugs for memory improvement" has been won by Krka's Bilobil. As in the last year, also this year Bilobil won the first place in its category.
More Pharma News ...
- Journalists from Argentina and Greece win Novo Nordisk Media Prize 2007
- InferMed appoints Cancer Research UK's Dr Sally Burtles as Observer to the Board
- Court Rules That Roche Infringes One of Amgen's Erythropoietin Patents
- Nexavar Significantly Improved Overall Survival in Phase III Asia-Pacific Liver Cancer Trial
- Pfizer Names Frank A. D'Amelio Chief Financial Officer
- Liraglutide improves glucose control and lowers body weight in two phase 3 studies
- GlaxoSmithKline Signs Contract for its Pandemic Flu Vaccine with UK Government